Literature DB >> 8982450

Bacterial diversity based on type II DNA topoisomerase genes.

W M Huang1.   

Abstract

Type II DNA topoisomerases are essential and ubiquitous DNA metabolic enzymes that alter DNA topology. Eubacteria have two indispensable type II DNA topoisomerases, DNA gyrase encoded by gyrB and gyrA and topoisomerase IV encoded by parE and parC. These genes belong to a single family whose members span both eukaryotes and prokaryotes. The highly conserved motifs in these genes provide a rationale for the design of universal primers used in the polymerase chain reaction in order to systematically generate a data set suitable for bacterial diversity studies at the macro-diversity level, as well as at the micro-diversity level displaying individual species and isolates. This family of genes is the subject of intensive biochemical and genetic analyses, which provide an opportunity for comprehensive understanding of sequence conservation and variability and their relationship to function. These genes are ideally suited for microbial identification and biodiversity analyses.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8982450     DOI: 10.1146/annurev.genet.30.1.79

Source DB:  PubMed          Journal:  Annu Rev Genet        ISSN: 0066-4197            Impact factor:   16.830


  42 in total

1.  Web-based phylogenetic assignment tool for analysis of terminal restriction fragment length polymorphism profiles of microbial communities.

Authors:  Angela D Kent; Dan J Smith; Barbara J Benson; Eric W Triplett
Journal:  Appl Environ Microbiol       Date:  2003-11       Impact factor: 4.792

2.  The alpha4 residues of human DNA topoisomerase IIalpha function in enzymatic activity and anticancer drug sensitivity.

Authors:  Namiko Suda; Yasutomo Ito; Tsuneo Imai; Toyone Kikumori; Akihiko Kikuchi; Yukihiro Nishiyama; Shonen Yoshida; Motoshi Suzuki
Journal:  Nucleic Acids Res       Date:  2004-03-16       Impact factor: 16.971

3.  A naturally chimeric type IIA topoisomerase in Aquifex aeolicus highlights an evolutionary path for the emergence of functional paralogs.

Authors:  Elsa M Tretter; Jeffrey C Lerman; James M Berger
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-12       Impact factor: 11.205

4.  First characterization of fluoroquinolone resistance in Streptococcus suis.

Authors:  Jose Antonio Escudero; Alvaro San Millan; Ana Catalan; Adela G de la Campa; Estefania Rivero; Gema Lopez; Lucas Dominguez; Miguel Angel Moreno; Bruno Gonzalez-Zorn
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

Review 5.  In front of and behind the replication fork: bacterial type IIA topoisomerases.

Authors:  Claudia Sissi; Manlio Palumbo
Journal:  Cell Mol Life Sci       Date:  2010-02-18       Impact factor: 9.261

6.  Emergence of a clonal lineage of Brucella abortus biovar 3 in clinical cases in Spain.

Authors:  Sylvia Valdezate; Ana Navarro; Virginia Rubio; Bruno Garin-Bastuji; David Albert; Purificación Hernandez; Pilar M Alonso; Juan A Saéz-Nieto
Journal:  J Clin Microbiol       Date:  2009-06-24       Impact factor: 5.948

7.  Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin.

Authors:  C M Bébéar; O Grau; A Charron; H Renaudin; D Gruson; C Bébéar
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

8.  Cloning and nucleotide sequences of the topoisomerase IV parC and parE genes of Mycoplasma hominis.

Authors:  C M Bébéar; A Charron; J M Bové; C Bébéar; J Renaudin
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

9.  Molecular characterization of the gene encoding the DNA gyrase A subunit of Streptococcus pneumoniae.

Authors:  D Balas; E Fernández-Moreira; A G De La Campa
Journal:  J Bacteriol       Date:  1998-06       Impact factor: 3.490

10.  Fluoroquinolones in the Treatment of Meningitis.

Authors:  Philippe Cottagnoud; Martin G. Täuber
Journal:  Curr Infect Dis Rep       Date:  2003-08       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.